NASDAQ: NVCR · Industrial Applications and Services · 6 alerts · CIK 1645113
Share price
$11.30Close, Nov 16
Market cap
$1.32B
Shares outstanding
116.92MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All NovoCure Ltd filings on SEC EDGAR ↗
NovoCure COO Mukund Paravasthu Sells $39.6K of Stock
Mukund Paravasthu, COO, sold 3,079 shares of NovoCure Ltd at $12.86 a share, worth $39.6K in total on Nov 9, 2026. Shares held after the trade: 69,753 (-4.2%).
NovoCure CFO Christoph Brackmann Sells $94.4K of Stock
Christoph Brackmann, CFO, sold 7,343 shares of NovoCure Ltd at $12.86 a share, worth $94.4K in total on Nov 9, 2026. Shares held after the trade: 175,499 (-4.0%).
NovoCure received a Not Approvable Letter from the FDA regarding its Premarket Approval (PMA) application for Optune Mya for treating brain metastases from non-small cell lung cancer. The FDA cited uncertainty regarding the degree of clinical benefit rather than safety concerns, and the company plans to meet with the regulator to discuss potential paths forward without additional clinical studies.
Novocure reported record third-quarter net revenues of $193.4 million, a 16% year-over-year increase driven by 19% growth in active patients. The company significantly narrowed its net loss to $10.4 million and raised its full-year 2026 revenue and adjusted EBITDA guidance based on strong commercial performance.
Term
Q3 2026
“Novocure’s strong third quarter performance was driven by continued growth in our Optune Gio business and our growing portfolio of products launching in new markets, resulting in a record number of active patients on our therapies.”
Frank Leonard, CEO, Novocure
“We achieved record-high quarterly net revenue and are well-positioned to achieve the commercial, clinical and financial goals we set out in January. Based on the results from this quarter, we have raised our financial guidance for 2026 and will continue to build on the strong progress we have made on our path to profitability.”
For the nine months ended September 30, 2026, NovoCure reported net revenues of $551.0 million, a 14.6% increase compared to the same period in 2025. Despite the revenue growth, the company recorded a net loss of $97.2 million for the first nine months of 2026, though this was an improvement from the $111.7 million net loss in the prior year period.